Results from drug repurposing screens using a yeast model of PGAP3 deficiency suggests cell death from ferroptosis as a pathomechanism, and phospholipase A2 activation as a therapeutic strategy.
Share this post
We found PGAP3 yeast hits! Now what?
Share this post
Results from drug repurposing screens using a yeast model of PGAP3 deficiency suggests cell death from ferroptosis as a pathomechanism, and phospholipase A2 activation as a therapeutic strategy.